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Intervention
Feasibility and SafetyConventionally, a combination of both ﬂuoroscopy
(FS) and cineangiography (CA) are used during per-
cutaneous coronary intervention (PCI). CA involves
higher radiation dosage exposure than regular FS (1).
However, FS-guided PCI has not been studied in
terms of safety and effectiveness in the past in a
randomized, controlled fashion versus conventional
CA-guided PCI.
We compared the procedural feasibility, safety,
radiation exposure, and short-term clinical outcomesTABLE 1 Comparison Between Fluoroscopy- and Cineangiography-Gu
Radiation Dosage
Fluoroscopy-Guided
(n ¼ 97)
Fluoroscopy time, min 6:52  2:58
Median 6:4
25th percentile 5:16
50th percentile 6:4
75th percentile 8:02
Procedure time, min 36.70  18.55
Air KERMA, mGy 785.19  67.50
Median 557.30
25th percentile 317.30
50th percentile 557.30
75th percentile 1,157.00
Cumulative DAP, mGym2 5,798.46  959.58
Median 3,927.20
25th percentile 2,229.10
50th percentile 3,927.20
75th percentile 6,040.50
Values are mean  SD and n (%). *Signiﬁcance was accepted at p < 0.05.
AE ¼ adverse events; BMS ¼ bare-metal stent; CAD ¼ coronary artery disease;
disease; EES ¼ everolimus-eluting stent; Hb ¼ hemoglobin; KERMA ¼ kinetic energy relea
LVEF ¼ left ventricular ejection fraction; MACE ¼ major adverse cardiac events; MI ¼ my
paclitaxel-eluting stent; RCA ¼ right coronary artery; STEMI ¼ ST-segment elevation musing FS alone with conventional FS- and CA-guided
PCI. This was a prospective, randomized controlled
trial. Between February 2013 and August 2013, 197
patients with 227 lesions underwent PCI. Patients
were randomized in a 1:1 ratio to a protocol of either
exclusive FS-guided PCI or combined use of FS and
CA guidance.
FS-guided intervention entailed signiﬁcantly
lower radiation exposure compared with CA guidance,
both in terms of air kinetic energy released per unit
mass (785.19 vs. 2,190.87) and dose–area product
(5,798.46 vs. 9,165.24). Procedure time trended toward
a lower time required for PCI in the FS group (36.7 min)
compared with the CA group (41.75 min), whereas
FS time was signiﬁcantly lower in the FS group
(6:52 min) than in the CA group (7:58 min) (Table 1).
There were no signiﬁcant differences in the inci-
dences of immediate procedural success, peri-
procedural myocardial infarction, and procedural
death. Major adverse cardiac events (MACEs) at 6
months were also similar in both arms. The mean
follow-up period was 6 months. The MACE rates were
2% and 3% in the FS and CA groups, respectivelyided Percutaneous Coronary Intervention
Cineangiography-Guided
(n ¼ 100) p Value
7:58  4:27 0.03*
7:55
4:09
7:55
10:33
41.75  24.30 0.07 (NS)
2,190.87  96.09 <0.01*
1,019.98
573.26
1,019.98
1,597.12
9,165.24  120.83 <0.01*
5,517.55
3,334.58
5,517.55
10,261.70
CSA ¼ chronic stable angina; DAP ¼ dose–area product; DVD ¼ double vessel
sed per unit mass; LAD ¼ left anterior descending artery; LCx ¼ left circumﬂex artery;
ocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PES ¼
yocardial infarction; USA ¼ unstable angina; ZES ¼ zotarolimus-eluting stent.
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402(p ¼ NS). There was no difference in reported adverse
events.
In conclusion, compared with conventional CA
guidance, FS alone was found to be an equally safe
and effective protocol, with similar immediate pro-
cedural and 6-month MACE rates, as well as similar
clinical outcomes for PCI, and had a signiﬁcantly
lower radiation at the source.Kamal H. Sharma, MD, DNB
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Diabetes and
Cardiovascular Risk
Reduction From High-Dose
Statin Therapy in Pre-Diabetics
and Non–Pre-DiabeticsAn Analysis From TNT and IDEALStatins reduce coronary and cerebrovascular events
in primary and secondary prevention. More intensive
statin therapy compared with moderate-intensity
statin therapy decreases risk even further (1).
Therefore, the 2013 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines
recommend high-intensity statin therapy in high-
risk patients. This recommendation is partly on the
basis of the documented safety of higher doses.
However, meta-analyses have reported a slight
increase in the risk of new-onset diabetes (NOD)
with statin therapy over placebo; this risk in-
creases by an additional 12% with high-intensity
therapy (2).Fasting blood glucose (FBG) >100 mg/dl is a strong
predictor of NOD; however, the incidence of NOD
during statin therapy in patients with pre-diabetes
(PD), which is deﬁned as a FBG of 100 to 126 mg/dl,
compared with those with normal glucose levels, has
not been previously reported. We describe the inci-
dence of NOD in patients with and without PD at
baseline from the TNT (Treating to New Targets) and
IDEAL (Incremental Decrease in Clinical Endpoints
Through Aggressive Lipid Lowering) randomized
clinical trials.
We pooled patients without diabetes at baseline
from both the TNT and IDEAL trials (3,4). The TNT
study randomized 10,001 patients with documented
coronary heart disease to atorvastatin 10 or 80
mg/day and followed them for a median of 4.9 years
(3). The IDEAL study randomized 8,888 patients with
a previous myocardial infarction (MI) to simvastatin
20 to 40 mg/day or atorvastatin 80 mg/day with a
median follow-up of 4.8 years (4).
The primary endpoint of our analysis was the
composite of coronary heart disease death, nonfatal
MI, resuscitated cardiac arrest, and stroke. NOD was
deﬁned prospectively as at least 2 post-baseline FBG
measurements $126 mg/dl or at least 1 post-baseline
FBG $36 mg/dl above baseline (5). FBG was
measured at each 12-month visit in TNT and at
randomization and at the end of study in IDEAL. We
also included patients who had NOD identiﬁed
through adverse event reporting or patients who
received new concomitant diabetic medication.
Of the total 15,056 patients from both trials without
diabetes at baseline, 5,924 (39%) had PD, and 9,132
(71%) patients did not. PD and non-PD patients were
evenly balanced across the statin treatment arms.
Compared with those without PD, PD patients were
more likely to be older, to be men, to have metabolic
syndrome, to have higher baseline blood pressure,
and to have a history of hypertension. PD patients
also had, on average, a higher body mass index,
higher FBG, higher triglyceride levels, and lower
levels of high-density lipoprotein cholesterol.
During the mean 5-year follow-up, 14.2% of PD
patients developed NOD compared with 2.9% of pa-
tients without PD (hazard ratio [HR]: 5.29, 95%
conﬁdence interval [CI]: 4.6 to 6.1; p <0.001). As
shown in Figure 1, the incidence of NOD was not time-
dependent, and occurred at the same rate throughout
the trial. In patients with PD, the risk of NOD was
higher in the high-intensity statin group (HR: 1.20,
95% CI: 1.04 to 1.37; p ¼ 0.010). In patients without
PD, the difference between the high- and moderate-
intensity treatment groups was not statistically
signiﬁcant (HR: 1.08, 95% CI: 0.85 to 1.38; p ¼ 0.527).
